Ipilimumab and Its Toxicities: A Multidisciplinary Approach

被引：237

作者：

Fecher, Leslie A. ^{[1
]}

Agarwala, Sanjiv S. ^{[2
]}

Hodi, F. Stephen ^{[3
]}

Weber, Jeffrey S. ^{[4
]}

机构：

[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[2] St Lukes Canc Ctr, Bethlehem, PA USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

来源：

ONCOLOGIST | 2013年 / 18卷 / 06期

关键词：

Ipilimumab; CTLA-4; Antibody; Melanoma; Immune-mediated toxicity; immune-related adverse events; AEOSI; METASTATIC MELANOMA; ANTI-CTLA4; ANTIBODY; AUTOIMMUNE HYPOPHYSITIS; INDUCED SARCOIDOSIS; CLINICAL-RESPONSE; CANCER; THERAPY; BLOCKADE; PATIENT; CTLA-4;

D O I：

10.1634/theoncologist.2012-0483

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The treatment for metastatic melanoma has evolved significantly in the past few years. Ipilimumab, an immunotherapy, is now in mainstream oncology practice given that it has shown improved overall survival in randomized clinical trials. Other immune modulating agents, such as programmed death receptor-1 and programmed death receptor ligand-1 antibodies, are showing promise in early clinical trials. This manuscript will review ipilimumab and its most common side effects. Immune-related adverse events (irAEs) are important to recognize early, and their presentation, timing of onset, and general recommendations for workup and management will be reviewed. Assembling a multidisciplinary team, as well as thorough education of the patient, is recommended to optimize patient care.

引用

页码：733 / 743

页数：11

共 56 条

[51]

Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission [J].

Vogel, Wouter V. ;

Guislain, Aurelie ;

Kvistborg, Pia ;

Schumacher, Ton N. M. ;

Haanen, John B. A. G. ;

Blank, Christian U. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (02) :E7-E10

[52]

Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events [J].

Weber, Jeffrey .

ONCOLOGIST, 2007, 12 (07) :864-872

[53]

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma [J].

Weber, Jeffrey ;

Thompson, John A. ;

Hamid, Omid ;

Minor, David ;

Amin, Asim ;

Ron, Ilan ;

Ridolfi, Ruggero ;

Assi, Hazem ;

Maraveyas, Anthony ;

Berman, David ;

Siegel, Jonathan ;

O'Day, Steven J. .

CLINICAL CANCER RESEARCH, 2009, 15 (17) :5591-5598

[54]

Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient [J].

Wilgenhof, S. ;

Neyns, B. .

ANNALS OF ONCOLOGY, 2011, 22 (04) :991-993

[55]

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study [J].

Wolchok, Jedd D. ;

Neyns, Bart ;

Linette, Gerald ;

Negrier, Sylvie ;

Lutzky, Jose ;

Thomas, Luc ;

Waterfield, William ;

Schadendorf, Dirk ;

Smylie, Michael ;

Guthrie, Troy, Jr. ;

Grob, Jean-Jacques ;

Chesney, Jason ;

Chin, Kevin ;

Chen, Kun ;

Hoos, Axel ;

O'Day, Steven J. ;

Lebbe, Celeste .

LANCET ONCOLOGY, 2010, 11 (02) :155-164

[56]

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis [J].

Yang, James C. ;

Hughes, Harybeth ;

Kammula, Udai ;

Royal, Riehard ;

Sherry, Riehard M. ;

Topalian, Suzanne L. ;

Suri, Kimberly B. ;

Levy, Catherine ;

Allen, Tamika ;

Mavroukakis, Sharon ;

Lowy, Israel ;

White, Donald E. ;

Rosenberg, Steven A. .

JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) :825-830

← 1 2 3 4 5 6 →